Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.
The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.
CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。